Synthesis and Optimization of Mesoporous Silica Nanoparticles for Ruthenium Polypyridyl Drug Delivery

The ruthenium polypyridyl complex [Ru(dppz)<sub>2</sub>PIP]<sup>2+</sup> (dppz: dipyridophenazine, PIP: (2-(phenyl)-imidazo[4,5-f ][1,10]phenanthroline), or Ru-PIP, is a potential anticancer drug that acts by inhibiting DNA replication. Due to the poor dissolution of Ru-PIP i...

Full description

Saved in:
Bibliographic Details
Main Authors: Siti Norain Harun (Author), Haslina Ahmad (Author), Hong Ngee Lim (Author), Suet Lin Chia (Author), Martin R. Gill (Author)
Format: Book
Published: MDPI AG, 2021-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_9aae4162b4bf455294d2345071fa84fd
042 |a dc 
100 1 0 |a Siti Norain Harun  |e author 
700 1 0 |a Haslina Ahmad  |e author 
700 1 0 |a Hong Ngee Lim  |e author 
700 1 0 |a Suet Lin Chia  |e author 
700 1 0 |a Martin R. Gill  |e author 
245 0 0 |a Synthesis and Optimization of Mesoporous Silica Nanoparticles for Ruthenium Polypyridyl Drug Delivery 
260 |b MDPI AG,   |c 2021-01-01T00:00:00Z. 
500 |a 10.3390/pharmaceutics13020150 
500 |a 1999-4923 
520 |a The ruthenium polypyridyl complex [Ru(dppz)<sub>2</sub>PIP]<sup>2+</sup> (dppz: dipyridophenazine, PIP: (2-(phenyl)-imidazo[4,5-f ][1,10]phenanthroline), or Ru-PIP, is a potential anticancer drug that acts by inhibiting DNA replication. Due to the poor dissolution of Ru-PIP in aqueous media, a drug delivery agent would be a useful approach to overcome its limited bioavailability. Mesoporous silica nanoparticles (MSNs) were synthesized via a co-condensation method by using a phenanthrolinium salt with a 16 carbon length chain (Phen-C<sub>16</sub>) as the template. Optimization of the synthesis conditions by Box-Behnken design (BBD) generated MSNs with high surface area response at 833.9 m<sup>2</sup>g<sup>−1</sup>. Ru-PIP was effectively entrapped in MSNs at 18.84%. Drug release profile analysis showed that Ru-PIP is gradually released, with a cumulative release percentage of approximately 50% at 72 h. The release kinetic profile implied that Ru-PIP was released from MSN by diffusion. The in vitro cytotoxicity of Ru-PIP, both free and MSN-encapsulated, was studied in Hela, A549, and T24 cancer cell lines. While treatment of Ru-PIP alone is moderately cytotoxic, encapsulated Ru-PIP exerted significant cytotoxicity upon all the cell lines, with half maximal inhibitory concentration (IC<sub>50</sub>) values determined by MTT (([3-(4,5-dimethylthiazol-2-yl)-2,5-dephenyltetrazolium bromide]) assay at 48 h exposure substantially decreasing from >30 µM to <10 µM as a result of MSN encapsulation. The mechanistic potential of cytotoxicity on cell cycle distribution showed an increase in G1/S phase populations in all three cell lines. The findings indicate that MSN is an ideal drug delivery agent, as it is able to sustainably release Ru-PIP by diffusion in a prolonged treatment period. 
546 |a EN 
690 |a mesoporous silica nanoparticles 
690 |a ruthenium polypyridyl 
690 |a drug delivery 
690 |a IC<sub>50</sub> 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceutics, Vol 13, Iss 2, p 150 (2021) 
787 0 |n https://www.mdpi.com/1999-4923/13/2/150 
787 0 |n https://doaj.org/toc/1999-4923 
856 4 1 |u https://doaj.org/article/9aae4162b4bf455294d2345071fa84fd  |z Connect to this object online.